Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

Inclusion Criteria: * Subjects who completed the TERMS study and received at least 1 study treatment injection * Signed and dated statement of informed consent Exclusion Criteria: * Pregnancy or breastfeeding * Experienced a serious adverse drug reaction with confirmatory relationship to Tovaxin in the TERMS study. * Withdrew from TERMS study and did not continue participating in the remaining 52-week core TERMS study assessments. * Non-compliant with TERMS study. * Diagnosis of progressive-relapsing, secondary progressive or primary progressive Multiple Sclerosis (MS) while enrolled in the TERMS study. * Medical, psychiatric or other conditions that compromise the subject's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study. * Any significant change in the subject's medical condition after enrollment in the TERMS study which would have lead to his/her exclusion from participation in that study.